Cargando…
Strength of clinical evidence leading to approval of novel cancer medicines in Europe: A systematic review and data synthesis
We aimed to evaluate the quality of clinical evidence that substantiated approval of cancer medicines by the European Medicines Agency (EMA) in the last decade. We performed a systematic review and data synthesis of EMA documents in agreement with PRISMA guidelines. We included the European Public A...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8262606/ https://www.ncbi.nlm.nih.gov/pubmed/34232554 http://dx.doi.org/10.1002/prp2.816 |
_version_ | 1783719218401771520 |
---|---|
author | Farina, Alberto Moro, Federico Fasslrinner, Frederick Sedghi, Annahita Bromley, Miluska Siepmann, Timo |
author_facet | Farina, Alberto Moro, Federico Fasslrinner, Frederick Sedghi, Annahita Bromley, Miluska Siepmann, Timo |
author_sort | Farina, Alberto |
collection | PubMed |
description | We aimed to evaluate the quality of clinical evidence that substantiated approval of cancer medicines by the European Medicines Agency (EMA) in the last decade. We performed a systematic review and data synthesis of EMA documents in agreement with PRISMA guidelines. We included the European Public Assessment Reports, Summaries of Product Characteristics, and published randomized controlled trials (RCTs) on anti‐cancer drugs approved by EMA from 2010 to 2019, and excluded drugs not indicated for targeting solid or hematological tumors and non‐innovative treatments. We synthesized frequencies of approvals differentiating between unblinded and blinded RCTs with and without overall survival (OS) as a predefined primary outcome measure. We assessed the frequency of post‐approval RCTs for indications without at least one RCT at the time of approval. Of 199 approvals, 159 (80%) were supported by at least one RCT, 63 (32%) by at least one RCT having OS as the primary or co‐primary endpoint, 74 (37%) by at least one blinded RCT, and 30 (15%) by at least one blinded RCT having OS as the primary or co‐primary endpoint. Whereas 40 approvals (20%) were not supported by any RCT and, of those, 9 (22%) were followed by a post‐approval RCT. While the majority of approvals of cancer medicines approved by EMA was supported by at least one RCT, we noted substantial methodological heterogeneity of the studies. Clinical trial registration: PROSPERO registration number CRD42020206669. |
format | Online Article Text |
id | pubmed-8262606 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-82626062021-07-13 Strength of clinical evidence leading to approval of novel cancer medicines in Europe: A systematic review and data synthesis Farina, Alberto Moro, Federico Fasslrinner, Frederick Sedghi, Annahita Bromley, Miluska Siepmann, Timo Pharmacol Res Perspect Original Articles We aimed to evaluate the quality of clinical evidence that substantiated approval of cancer medicines by the European Medicines Agency (EMA) in the last decade. We performed a systematic review and data synthesis of EMA documents in agreement with PRISMA guidelines. We included the European Public Assessment Reports, Summaries of Product Characteristics, and published randomized controlled trials (RCTs) on anti‐cancer drugs approved by EMA from 2010 to 2019, and excluded drugs not indicated for targeting solid or hematological tumors and non‐innovative treatments. We synthesized frequencies of approvals differentiating between unblinded and blinded RCTs with and without overall survival (OS) as a predefined primary outcome measure. We assessed the frequency of post‐approval RCTs for indications without at least one RCT at the time of approval. Of 199 approvals, 159 (80%) were supported by at least one RCT, 63 (32%) by at least one RCT having OS as the primary or co‐primary endpoint, 74 (37%) by at least one blinded RCT, and 30 (15%) by at least one blinded RCT having OS as the primary or co‐primary endpoint. Whereas 40 approvals (20%) were not supported by any RCT and, of those, 9 (22%) were followed by a post‐approval RCT. While the majority of approvals of cancer medicines approved by EMA was supported by at least one RCT, we noted substantial methodological heterogeneity of the studies. Clinical trial registration: PROSPERO registration number CRD42020206669. John Wiley and Sons Inc. 2021-07-07 /pmc/articles/PMC8262606/ /pubmed/34232554 http://dx.doi.org/10.1002/prp2.816 Text en © 2021 The Authors. Pharmacology Research & Perspectives published by British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics and John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Articles Farina, Alberto Moro, Federico Fasslrinner, Frederick Sedghi, Annahita Bromley, Miluska Siepmann, Timo Strength of clinical evidence leading to approval of novel cancer medicines in Europe: A systematic review and data synthesis |
title | Strength of clinical evidence leading to approval of novel cancer medicines in Europe: A systematic review and data synthesis |
title_full | Strength of clinical evidence leading to approval of novel cancer medicines in Europe: A systematic review and data synthesis |
title_fullStr | Strength of clinical evidence leading to approval of novel cancer medicines in Europe: A systematic review and data synthesis |
title_full_unstemmed | Strength of clinical evidence leading to approval of novel cancer medicines in Europe: A systematic review and data synthesis |
title_short | Strength of clinical evidence leading to approval of novel cancer medicines in Europe: A systematic review and data synthesis |
title_sort | strength of clinical evidence leading to approval of novel cancer medicines in europe: a systematic review and data synthesis |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8262606/ https://www.ncbi.nlm.nih.gov/pubmed/34232554 http://dx.doi.org/10.1002/prp2.816 |
work_keys_str_mv | AT farinaalberto strengthofclinicalevidenceleadingtoapprovalofnovelcancermedicinesineuropeasystematicreviewanddatasynthesis AT morofederico strengthofclinicalevidenceleadingtoapprovalofnovelcancermedicinesineuropeasystematicreviewanddatasynthesis AT fasslrinnerfrederick strengthofclinicalevidenceleadingtoapprovalofnovelcancermedicinesineuropeasystematicreviewanddatasynthesis AT sedghiannahita strengthofclinicalevidenceleadingtoapprovalofnovelcancermedicinesineuropeasystematicreviewanddatasynthesis AT bromleymiluska strengthofclinicalevidenceleadingtoapprovalofnovelcancermedicinesineuropeasystematicreviewanddatasynthesis AT siepmanntimo strengthofclinicalevidenceleadingtoapprovalofnovelcancermedicinesineuropeasystematicreviewanddatasynthesis |